Author: ollipulkka

Sartar was awarded a USA patent for use of anagrelide in cancer therapy.

Sartar Therapeutics participated to the HealthBIO pitching competition and won it.

http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/

 

Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November.

https://ebdgroup.knect365.com/bioeurope/

 

Sartar participates in HealthBIO partnering event.

http://www.healthbio.fi/

SPARK Finland program is designed to increase the maturity of academic and clinical discoveries towards practical solutions in the life science and health tech space.

http://sparkfinland.fi/